- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00335049
Study of Theories About Myopia Progression (STAMP)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Eligible children will be enrolled, randomized, and followed at six-month intervals for two years with all children wearing single vision lenses for the second year. At each visit, complete measurements of the components of the eye will be made to explain the mechanism responsible for the Progressive Addition Lens (PAL) treatment effect and why it occurs mainly during the first year of bifocal wear (Gwiazda et al. 2003). While hyperopic retinal blur (blur at the back of the eye) due to accommodative lag (poor focusing when doing close work) has been proposed as a possible mechanism driving myopia progression (Gwiazda et al. 1993), others have shown that accommodative lag accompanies rather than precedes the onset of myopia (Mutti et al., 2006). This suggests that accommodative lag is a result of another possible mechanism resulting in myopia progression such as crystalline lens-induced ciliary-choroidal tension (a model in which the lens in the eye is stretched and is not as good at focusing up close) (Mutti et al., 2000). According to this proposed mechanism, high accommodative lag in myopia results from increased crystalline lens tension that is transmitted through the choroid (an outside layer of the eye). This tension results in restricted equatorial (the vertical dimension of the eye) eye growth with no axial (front to back) restriction to eye growth and yields a prolate ocular shape (an eye that is longer than it is wide) in myopes (Mutti et al., 2000).
Comparisons: Refractive error (glasses prescription), axial length (length of the eye), peripheral eye shape, accommodation (focusing ability), corneal shape (shape of the front of the eye), anterior chamber depth, crystalline lens thickness and curvatures (shape of the lens in the eye), central and peripheral higher-order aberrations (how well light focuses in the eye), and phoria (eye alignment) will be measured at six-month intervals. The primary study outcome is refractive error measured by cycloplegic autorefraction. Comparison of the biometric data collected both during the first year when the PAL intervention is present and during the second year when the PAL intervention is removed will allow us to differentiate between the two theories under consideration. We will also evaluate whether the modest PAL treatment effect that has been reported during the first year of PAL wear is permanent.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- The Ohio State University College of Optometry
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 6 to 11 years of age
- Best corrected vision of at least 20/30 in each eye
- Birth weight > 1250g
(The criteria below will be evaluated at a screening visit to find out if the child can participate)
- Accommodative lag >= 1.30 D (for a 4D stimulus)
- At least -0.75 D myopia in each meridian measured with cycloplegic autorefraction but not more than -4.50 D in each meridian in each eye
- Esophoria at near if more than -2.25 D spherical equivalent (high myopia)
- Astigmatism < 2.00 DC in each eye
- Anisometropia < 2.00 D
Exclusion Criteria:
- Strabismus (eye turn)
- History of contact lens wear
- History of previous bifocal wear
- Diabetes mellitus
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: PAL
Progressive Addition Spectacle Lenses (PALs) with a +2.00 D add worn for first year off study.
Single Vision Lenses worn for second year of study.
|
Progressive addition lenses (PAL) with a +2.00 D add.
Other Names:
|
|
Active Comparator: SVL
Single Vision Lenses (SVLs) worn both years of the study.
|
Single vision spectacle lenses.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Cycloplegic autorefraction
Time Frame: Baseline, 6, 12, 18, and 24 months
|
Baseline, 6, 12, 18, and 24 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Phoria
Time Frame: Baseline, 6, 12, 18, and 24 months
|
Baseline, 6, 12, 18, and 24 months
|
|
Accommodative lag
Time Frame: Baseline, 6, 12, 18, and 24 months
|
Baseline, 6, 12, 18, and 24 months
|
|
AC/A ratio
Time Frame: Baseline, 6, 12, 18, and 24 months
|
Baseline, 6, 12, 18, and 24 months
|
|
Corneal shape and thickness
Time Frame: Baseline, 6, 12, 18, and 24 months
|
Baseline, 6, 12, 18, and 24 months
|
|
Intraocular pressure
Time Frame: Baseline, 6, 12, 18, and 24 months
|
Baseline, 6, 12, 18, and 24 months
|
|
Peripheral ocular shape
Time Frame: Baseline, 6, 12, 18, and 24 months
|
Baseline, 6, 12, 18, and 24 months
|
|
Central and peripheral aberrations
Time Frame: Baseline, 6, 12, 18, and 24 months
|
Baseline, 6, 12, 18, and 24 months
|
|
Crystalline lens thickness and curvature
Time Frame: Baseline, 6, 12, 18, and 24 months
|
Baseline, 6, 12, 18, and 24 months
|
|
Anterior chamber depth
Time Frame: Baseline, 6, 12, 18, and 24 months
|
Baseline, 6, 12, 18, and 24 months
|
|
Axial length
Time Frame: Baseline, 6, 12, 18, and 24 months
|
Baseline, 6, 12, 18, and 24 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: David A Berntsen, OD, PhD, University of Houston
- Principal Investigator: Karla Zadnik, OD, PhD, Ohio State University
Publications and helpful links
General Publications
- Gwiazda J, Hyman L, Hussein M, Everett D, Norton TT, Kurtz D, Leske MC, Manny R, Marsh-Tootle W, Scheiman M. A randomized clinical trial of progressive addition lenses versus single vision lenses on the progression of myopia in children. Invest Ophthalmol Vis Sci. 2003 Apr;44(4):1492-500. doi: 10.1167/iovs.02-0816.
- Gwiazda J, Thorn F, Bauer J, Held R. Myopic children show insufficient accommodative response to blur. Invest Ophthalmol Vis Sci. 1993 Mar;34(3):690-4.
- Mutti DO, Sholtz RI, Friedman NE, Zadnik K. Peripheral refraction and ocular shape in children. Invest Ophthalmol Vis Sci. 2000 Apr;41(5):1022-30.
- Mutti DO, Mitchell GL, Hayes JR, Jones LA, Moeschberger ML, Cotter SA, Kleinstein RN, Manny RE, Twelker JD, Zadnik K; CLEERE Study Group. Accommodative lag before and after the onset of myopia. Invest Ophthalmol Vis Sci. 2006 Mar;47(3):837-46. doi: 10.1167/iovs.05-0888.
- Berntsen DA, Barr CD, Mutti DO, Zadnik K. Peripheral defocus and myopia progression in myopic children randomly assigned to wear single vision and progressive addition lenses. Invest Ophthalmol Vis Sci. 2013 Aug 27;54(8):5761-70. doi: 10.1167/iovs.13-11904.
- Berntsen DA, Sinnott LT, Mutti DO, Zadnik K. A randomized trial using progressive addition lenses to evaluate theories of myopia progression in children with a high lag of accommodation. Invest Ophthalmol Vis Sci. 2012 Feb 13;53(2):640-9. doi: 10.1167/iovs.11-7769. Print 2012 Feb.
- Berntsen DA, Mutti DO, Zadnik K. The effect of bifocal add on accommodative lag in myopic children with high accommodative lag. Invest Ophthalmol Vis Sci. 2010 Dec;51(12):6104-10. doi: 10.1167/iovs.09-4417. Epub 2010 Aug 4.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2005H0157
- K12EY015447 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.